{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:11:36Z","timestamp":1790831496958,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010458.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T00:00:00Z","timestamp":1599350400000}}],"reference-count":55,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010458.pub3","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T09:14:19Z","timestamp":1599383659000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tafenoquine for preventing relapse in people with <i>Plasmodium vivax<\/i> malaria"],"prefix":"10.1002","volume":"2024","author":[{"given":"Chaturaka","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medical Sciences; University of New South Wales; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senaka","family":"Rajapakse","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine; Faculty of Medicine, University of Colombo; Colombo Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Fernando","sequence":"additional","affiliation":[{"name":"Department of Parasitology; Faculty of Medicine, University of Colombo; Colombo Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,6]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria","volume":"380","author":"Lacerda","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010458.pub3-BIB0002|cit2","first-page":"14","article-title":"Dose-ranging efficacy results from the tafenoquine 'detective' trial: a randomized, double-blind, multi-centre, parallel-group study for the radical cure of subjects with Plasmodium vivax malaria","volume":"89","author":"Lacerda","year":"2013","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"9922","key":"10.1002\/14651858.CD010458.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study","volume":"383","author":"Llanos-Cuentas","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010458.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-019-00839-w","article-title":"Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers","volume":"42","author":"Ackert","year":"2019","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2875-13-49","article-title":"A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area","volume":"13","author":"Dow","year":"2014","journal-title":"Malaria Journal"},{"issue":"12","key":"10.1002\/14651858.CD010458.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1086\/379718","article-title":"Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis","volume":"37","author":"Edstein","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010458.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.trstmh.2008.04.024","article-title":"The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific","volume":"102","author":"Elmes","year":"2008","journal-title":"Transactions of Royal Society of Tropical Medicine and Hygiene"},{"issue":"11","key":"10.1002\/14651858.CD010458.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e0187376","DOI":"10.1371\/journal.pone.0187376","article-title":"A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria","volume":"12","author":"Fukuda","year":"2017","journal-title":"PloS One"},{"issue":"9","key":"10.1002\/14651858.CD010458.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.302","article-title":"Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects","volume":"54","author":"Green","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010458.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/367542","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum","volume":"36","author":"Hale","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4269\/ajtmh.2007.76.494","article-title":"Tafenoquine for the treatment of recurrent Plasmodium vivax malaria","volume":"76","author":"Kitchener","year":"2007","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"9220","key":"10.1002\/14651858.CD010458.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(00)02352-7","article-title":"Malaria chemoprophylaxis with tafenoquine: a randomised study","volume":"355","author":"Lell","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD010458.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0035-9203(02)90351-2","article-title":"Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel","volume":"96","author":"Nasveld","year":"2002","journal-title":"Transactions of Royal Society of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1002\/14651858.CD010458.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"10.1002\/14651858.CD010458.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1086\/324081","article-title":"A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria","volume":"33","author":"Shanks","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD010458.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/315034","article-title":"Randomized dose-ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand","volume":"180","author":"Walsh","year":"1999","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010458.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1086\/424508","article-title":"Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse","volume":"39","author":"Walsh","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010458.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1086\/424468","article-title":"Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria","volume":"190","author":"Walsh","year":"2004","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0020|cit20","unstructured":"Efficacy and safety study of tafenoquine (TQ) co-administered with dihydroartemisinin-piperaquine (DHA-PQP) for the radical cure of Plasmodium vivax (P. vivax) malaria clinicaltrials.gov\/ct2\/show\/NCT02802501"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0021|cit21","unstructured":"Effectiveness of novel approaches to radical cure with tafenoquine and primaquine (EFFORT) clinicaltrials.gov\/ct2\/show\/NCT04411836"},{"issue":"9","key":"10.1002\/14651858.CD010458.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/424663","article-title":"Primaquine therapy for malaria","volume":"39","author":"Baird","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010458.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1128\/CMR.00074-12","article-title":"Evidence and implications of mortality associated with acute Plasmodium vivax malaria","volume":"26","author":"Baird","year":"2013","journal-title":"Clinical Microbiology Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010458.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/infdis\/jiv508","article-title":"Estimation of the antirelapse efficacy of tafenoquine, using Plasmodium vivax genotyping","volume":"2135","author":"Beck","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD010458.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4269\/ajtmh.19-0001","article-title":"Approval of tafenoquine for malaria chemoprophylaxis","volume":"100","author":"Berman","year":"2019","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"5","key":"10.1002\/14651858.CD010458.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD010458.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","article-title":"First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial","volume":"58","author":"Brueckner","year":"1998","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1002\/14651858.CD010458.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4269\/ajtmh.2009.80.188","article-title":"Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment","volume":"80","author":"Carmona-Fonseca","year":"2009","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"1","key":"10.1002\/14651858.CD010458.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12936-019-2774-2","article-title":"Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor","volume":"18","author":"Chen","year":"2019","journal-title":"Malaria Journal"},{"issue":"5","key":"10.1002\/14651858.CD010458.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543784.16.5.705","article-title":"Tafenoquine: a promising new antimalarial agent","volume":"16","author":"Crockett","year":"2007","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"1","key":"10.1002\/14651858.CD010458.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12916-014-0217-z","article-title":"Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia","volume":"12","author":"Douglas","year":"2014","journal-title":"BMC Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010458.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1995-7645(11)60098-9","article-title":"Chemoprophylaxis in malaria: drugs, evidence of efficacy and costs","volume":"4","author":"Fernando","year":"2011","journal-title":"Asian Pacific Journal of Tropical Medicine"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1475-2875-10-351","article-title":"Primaquine in vivax malaria: an update and review on management issues","volume":"10","author":"Fernando","year":"2011","journal-title":"Malaria Journal"},{"issue":"9","key":"10.1002\/14651858.CD010458.pub3-BIB0034|cit34","first-page":"499","article-title":"Plasmochin in the treatment of malaria","volume":"62","author":"Fletcher","year":"1927","journal-title":"Indian Medical Gazette"},{"issue":"2","key":"10.1002\/14651858.CD010458.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4269\/ajtmh.2007.76.203","article-title":"Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy","volume":"76","author":"Goller","year":"2007","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0036|cit36","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2014"},{"issue":"7414","key":"10.1002\/14651858.CD010458.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0038|cit38","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","article-title":"Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I","volume":"75","author":"Hill","year":"2006","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010458.pub3-BIB0040|cit40","first-page":"14","article-title":"Dose-ranging efficacy results from the tafenoquine 'detective' trial: a randomized, double-blind, multi-centre, parallel-group study for the radical cure of subjects with Plasmodium vivax malaria","volume":"89","author":"Lacerda","year":"2013","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0041|cit41","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD010458.pub3-BIB0042|cit42","first-page":"187","article-title":"Tafenoquine: a new 8-aminoquinoline","volume":"36","author":"Prashar","year":"2009","journal-title":"Medical Journal of Zambia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD010458.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4269\/ajtmh.2007.77.79","article-title":"Vivax malaria: neglected and not benign","volume":"77","author":"Price","year":"2007","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"10","key":"10.1002\/14651858.CD010458.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S1473-3099(14)70855-2","article-title":"Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis","volume":"14","author":"Price","year":"2014","journal-title":"Lancet Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD010458.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1413-8670(10)70084-2","article-title":"Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon","volume":"14","author":"Ramos J\u00fanior","year":"2010","journal-title":"Brazilian Journal of Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010458.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3201\/eid1211.060613","article-title":"Plasmodium vivax malaria relapses after primaquine prophylaxis","volume":"12","author":"Reddy","year":"2006","journal-title":"Emerging Infectious Diseases"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0047|cit47","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers","volume":"97","author":"Rueangweerayut","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0049|cit49","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A GRADE handbook for grading quality of evidence and strength of recommendations Available from guidelinedevelopment.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pt.2009.12.005","article-title":"Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination","volume":"26","author":"Wells","year":"2010","journal-title":"Trends in Parasitology"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0051|cit51","volume-title":"Guidelines for the Treatment of Malaria","author":"World Health Organization","year":"2015"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0052|cit52","volume-title":"Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria; Policy brief","author":"World Health Organization","year":"2016"},{"key":"10.1002\/14651858.CD010458.pub3-BIB0053|cit53","unstructured":"World Health Organization World Malaria Report 2018 www.who.int\/malaria\/publications\/world-malaria-report-2018\/report\/en\/"},{"issue":"3","key":"10.1002\/14651858.CD010458.pub3-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010458","article-title":"Tafenoquine for Plasmodium vivax malaria infection","author":"Rajapakse","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010458.pub3-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010458.pub2","article-title":"Tafenoquine for preventing relapse in people with Plasmodium vivax malaria","author":"Rajapakse","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:06:30Z","timestamp":1744589190000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010458.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,6]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010458.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,6]]}}}